Search research articles
Contact Us
Filters
Showing results (141-150 of 221) with videos related to
Page
of 23
Sort By:
Research and Practice in Thrombosis and Haemostasis
|
November 9, 2022
Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban-treated patients and healthy controls
Jonathan Evrard, Romain Siriez, Céline Bouvy, et al.
The Annals of Pharmacotherapy
|
July 2, 2014
Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study
Anne-Sophie Larock, François Mullier, Anne-Laure Sennesael, et al.
Contraception
|
September 21, 2020
Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters
Jonathan Douxfils, Christine Klipping, Ingrid Duijkers, et al.
Research and Practice in Thrombosis and Haemostasis
|
November 11, 2021
Interlaboratory variability of activated protein C resistance using the ETP-based APC resistance assay
Laure Morimont, Marie Didembourg, Hélène Haguet, et al.
Journal of Medical Virology
|
January 8, 2024
Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster
Julien Favresse, Constant Gillot, Mélanie Closset, et al.
Journal of the American Heart Association
|
June 8, 2014
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
Jonathan Douxfils, Fanny Buckinx, François Mullier, et al.
Thrombosis Research
|
August 8, 2015
Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study
Sarah Lessire, Jonathan Douxfils, Justine Baudar, et al.
Journal of Medical Virology
|
September 21, 2022
Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
Julien Favresse, Constant Gillot, Jean-Louis Bayart, et al.
Thrombosis Research
|
January 31, 2024
A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban
Karl Mangion, Kevin Vella, Alex Gatt, et al.
Virology
|
April 18, 2024
Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273
Constant Gillot, Marie Tré-Hardy, Roberto Cupaiolo, et al.
Page
of 23
Search research articles
Search
Showing results (141-150 of 221) with videos related to
Sort By:
Page
of 23
Research and Practice in Thrombosis and Haemostasis
|
November 9, 2022
Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban-treated patients and healthy controls
Jonathan Evrard, Romain Siriez, Céline Bouvy, et al.
The Annals of Pharmacotherapy
|
July 2, 2014
Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study
Anne-Sophie Larock, François Mullier, Anne-Laure Sennesael, et al.
Contraception
|
September 21, 2020
Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters
Jonathan Douxfils, Christine Klipping, Ingrid Duijkers, et al.
Research and Practice in Thrombosis and Haemostasis
|
November 11, 2021
Interlaboratory variability of activated protein C resistance using the ETP-based APC resistance assay
Laure Morimont, Marie Didembourg, Hélène Haguet, et al.
Journal of Medical Virology
|
January 8, 2024
Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster
Julien Favresse, Constant Gillot, Mélanie Closset, et al.
Journal of the American Heart Association
|
June 8, 2014
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
Jonathan Douxfils, Fanny Buckinx, François Mullier, et al.
Thrombosis Research
|
August 8, 2015
Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study
Sarah Lessire, Jonathan Douxfils, Justine Baudar, et al.
Journal of Medical Virology
|
September 21, 2022
Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
Julien Favresse, Constant Gillot, Jean-Louis Bayart, et al.
Thrombosis Research
|
January 31, 2024
A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban
Karl Mangion, Kevin Vella, Alex Gatt, et al.
Virology
|
April 18, 2024
Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273
Constant Gillot, Marie Tré-Hardy, Roberto Cupaiolo, et al.
Page
of 23